

Bergen Brunswig Reports Record Third Quarter Revenues and Operating Earnings June 30, 2001

July 26, 2001

Earnings from Continuing Operations Increase 78% Revenues from Continuing Operations Increase to \$5.5 Billion

ORANGE, Calif.--July 26, 2001-- Bergen Brunswig Corporation today announced results for the period ended June 30, 2001 -- the Company's third quarter of fiscal 2001.

For the third quarter, revenues from continuing operations, excluding bulk shipments, increased 14% to a record \$5.5 billion, which compares to \$4.8 billion last year. Operating earnings from continuing operations rose to a record \$98.6 million for the quarter, up 34% from the year-ago period. Earnings before interest, taxes, depreciation and amortization (EBITDA) were \$115.7 million for the quarter, an increase of 23% from last year's third quarter EBITDA.

Net earnings and earnings from continuing operations were \$35.2 million for the third quarter, up 78% from last year's earnings from continuing operations of \$19.7 million. Last year's net loss for the quarter, including losses from discontinued operations and dispositions related to the sale of Bergen Brunswig Medical Corporation and Stadlander, was \$239.4 million.

Diluted earnings per share from continuing operations were \$0.26 compared to \$0.15 for the third quarter last year, an increase of 73%. Diluted loss per share including discontinued operations and dispositions was \$1.78 for the third quarter of last year. Weighted average diluted shares outstanding were 137.3 million in fiscal 2001 versus 134.5 million for the third quarter last year.

For the nine months ended June 30, 2001 revenues from continuing operations, excluding bulk shipments, increased 10% to \$15.2 billion which compares to \$13.9 billion last year. Operating earnings from continuing operations rose 22% to \$264.3 million for the first nine months of fiscal 2001 compared to \$217.4 million for the same period a year ago. EBITDA from continuing operations increased 13% in the first nine months of fiscal 2001 to \$315.6 million from \$279.4 million for the same period last year.

For the nine months, net earnings and earnings from continuing operations were \$84.7 million, up 32% from last year's earnings from continuing operations of \$64.3 million. Last year's net loss of \$207.5 million included losses from discontinued operations and dispositions.

Diluted earnings per share from continuing operations were \$0.62 for the nine months compared to \$0.48 for the first nine months of fiscal 2000, an increase of 29%. Diluted loss per share including discontinued operations and dispositions was \$1.54 for the first nine months of last year. Weighted average diluted shares outstanding were 136.8 million for the first nine months of fiscal 2001 versus 134.5 million for the first nine months of fiscal 2000.

"Last year at this time we stated our resolve to focus on our core expertise in both our major business segments, pharmaceutical distribution and PharMerica, in a concerted effort to enhance shareowner value," commented Robert E. Martini, Bergen's Chairman of the Board and CEO. "We have done just that. Our current quarter's results show record revenues and operating earnings as well as FIFO operating margin improvements and demonstrate that our strategies are succeeding.

"While many industries have been adversely affected by changes in the economy, the healthcare industry is generally recession-resistant. We continue to see positive trends in our business as the demand for pharmaceutical products increases, generic drug usage grows as branded products come off patent, lower interest rates prevail, and our operations become increasingly efficient. All in all, we believe the economic climate continues to shift in our favor."

Segment Review

Pharmaceutical Distribution Segment

This segment, comprised of Bergen Brunswig Drug Company (BBDC) and Bergen Brunswig Specialty Group (BBSG), increased revenues 14% in the third quarter to \$5.3 billion and 10% to \$14.8 billion for the nine months. Operating earnings for the pharmaceutical distribution segment increased 12% to \$102.5 million for the quarter. For the nine month period, operating earnings increased 9% to \$275.8 million.

Bergen Brunswig Drug Company

BBDC reported a 12% revenue increase for the quarter, reporting a record \$4.9 billion. For the nine months, revenues were \$13.6 billion, an 8% increase over the prior year.

"We are very pleased to report our third consecutive quarter of sales, earnings and operating expense margin improvement, despite difficult revenue comparisons to last year," said Brent R. Martini, President, BBDC. "Our customer, supplier and internal initiatives are favorably impacting profitability."

During the quarter, BBDC renewed several prime vendor contracts. Raley's signed a five-year \$3 billion prime vendor contract with BBDC that includes a two year extension. BBDC has served Raley's, which operates supermarkets in California, Nevada, and New Mexico, for nearly 10 years, and the signing of this contract exemplifies the strong, long-term nature of its relationships with its customers.

BBDC also announced an exclusive five-year contract with Big A Drug Stores, which includes 15 Drug Emporium stores recently acquired by the Big A chain, providing \$80 million in incremental revenues to Bergen annually. Additionally, BBDC renewed its contract with May's Drug Stores, which is expected to generate \$100 million in revenues to Bergen annually. BBDC will continue to be the primary provider for pharmaceuticals to May's 39 stores in Northeast Oklahoma and Southwest Missouri.

During the quarter, the Drug Company and Longs Drug Stores successfully opened the first central fill facility to be jointly operated by a wholesaler and a retailer. The success of this new operation demonstrates BBDC's commitment to create and implement logistical solutions for its customers.

This central fill facility, Escalante Solutions, is now processing prescriptions for selected Longs stores in Northern California and Nevada. Escalante

uses Automed(TM) robotic technology and PDX software solutions to help alleviate capacity issues caused by a growing pharmacist shortage and strong prescription growth. Escalante Solutions promotes accuracy in prescription filling and productivity improvements in the pharmacy operation, allowing community pharmacists to spend more time counseling patients.

BBDC continued to expand its Internet based applications and offerings. iBergen(SM), the Company's Internet portal for pharmaceutical services, was enhanced to include manufacturer and new product announcements, stock quotes, newsfeeds, on-line product information and generic usage analysis tools. In addition, the Company unveiled its first personalized community and content area on the site, designed for the unique needs of its GNP customers. The area is known as the GNP Community and serves the Company's more than 2000 independent Good Neighbor Pharmacies. BBDC enhanced the Catalog & Order Entry application on iBergen through a new version release, and introduced iScan(TM), a powerful barcode system. iScan optimizes the supply chain by providing efficiencies and accuracy in productivity through receiving and accounts payable matching. iScan is currently in use by select customers and will provide a technology platform for expanding barcode capabilities.

Enhancements to the Drug Company's electronic solutions for retail pharmacy introduced at its fifth annual Healthcare Congress and Manufacturers' Exposition held recently in Las Vegas were received enthusiastically by attendees. A Generic Summit was added to complement last year's successful Branded Rx Summit, providing an opportunity for one-on-one information exchange between pharmacists and major generic manufacturers. The 27 continuing education courses held over a two-day period had record attendance and included courses on subjects as diverse as the use of the Internet in retail pharmacy to compounding of special prescriptions.

Bergen Brunswick Specialty Group

BBSG delivered a 41% revenue gain for the quarter to \$441.6 million and 34% to \$1.2 billion for the nine months, relative to the prior year.

Growth was again driven by the unit's oncology division, which exceeded financial expectations and increased sales by more than 60% relative to last year. Much of the oncology division's success can be attributed to consistent execution in its core operations and sustained market penetration by its sales staff. Additional factors include uninterrupted membership growth of its physician services partner which added over 95 new accounts in the quarter.

Additionally, BBSG's vaccine business, Besse Medical, also contributed significantly to sales growth by increasing its sales 35% for the quarter, relative to last year. Much of the growth continues to be driven by the group's focus on the biotech markets, particularly in the area of rheumatology. The vaccine market continues to be challenged by manufacturing problems resulting in limited availability of many key vaccines and other injectable products.

BBSG's manufacturing services increased year-over-year sales by 30%, contributing to the specialty group's success in the quarter.

PharMerica Segment revenues were \$336.8 million for the third quarter and \$1.0 billion for the nine months ending June 30, 2001, representing an increase of 5% and 6% over the prior periods, respectively. PharMerica's operating earnings increased to \$16.0 million for the third quarter of fiscal 2001, which compares to an operating loss of \$1.7 million for the same quarter a year ago. For the nine months operating earnings increased 225% to \$47.3 million.

PharMerica's EBITDA increased 155% to \$23.5 million for the third quarter, compared to last year's EBITDA of \$9.2 million. For the nine months ended June 30, 2001, EBITDA increased 47% compared to last year, to \$69.8 million.

Operating expenses, as a percent of sales, were 30% for this year's third quarter comparing favorably to last year's 37%. For the nine months, operating expenses as a percent of sales improved to 31% compared to 36% last year. Improvement in bad debt expense and lower goodwill amortization were the primary reasons for these results; however, PharMerica's long term care business continues to see improvements in administrative and other expenses as well.

In the third quarter, PharMerica extended its agreement with its largest customer, Beverly Enterprises, through March of 2006. Beverly Enterprises represents approximately 24% of the Company's LTC revenue base. PharMerica is committed to partnering with Beverly, and its other major customers, to remove costs from the pharmacy delivery system while improving service and patient outcomes.

PharMerica has experienced cash collections for the third quarter and on a year-to-date basis of 103% of revenues and 100% of revenues, respectively. Gross and net days sales outstanding (DSO) for PharMerica were 72 and 50 days, respectively, at June 30, 2001. The gross and net DSOs were 90 and 71 days, respectively, at June 30, 2000.

PMSI, PharMerica's workers compensation and catastrophic care business that provides PBM services along with home delivery of pharmaceutical and medical products, continues to report substantial growth. Revenues for this division grew 37% in this year's third quarter compared to last year's third quarter. On a year-to-date basis, PMSI's revenues this year have increased 36%. PMSI continues to add new customers, principally the larger insurance carriers, reflecting the success of its business model in the marketplace.

Summary

"The strength of this quarter's financial results for each of our businesses illustrates the wisdom of our business strategies," commented Neil F. Dimick, Bergen's Chief Financial Officer. "BBDC's sales growth is back in double digits; each of BBSG's divisions is experiencing rapid growth, led by its oncology unit; and PharMerica's earnings have stabilized and improved.

"We're confident that we will be able to meet our expectations for revenues and earnings growth of 10% and 30% respectively."

AmeriSource Bergen Merger

The merger of AmeriSource Health Corporation and Bergen Brunswick Corporation, announced March 19, 2001, continues to move towards an expected completion date in late August of this year.

"The integration process has proceeded as planned between the two companies and the operating efficiencies have been confirmed as anticipated. We are expecting to close the transaction after the FTC and the shareholders approve the merger," said Dimick.

Conference Call Today

The senior management of Bergen Brunswig will hold a conference call today at 11:00 a.m. PDT to discuss the quarter in more detail. To access the call dial (913) 981-5532 ten minutes prior to the call. The Company will also make a replay available ending August 1, 2001 at noon PDT. The toll-free replay number is (888) 203-1112. The pass code for both calls is 537789.

The call will also be available via webcast at www.vcall.com.

About Bergen Brunswig

Bergen Brunswig Corporation, headquartered in Orange County, California, is a leading supplier of pharmaceuticals and specialty healthcare products as well as information management solutions and consulting services. With \$22 billion in annualized operating revenues, Bergen's customers include the nation's healthcare providers (hospitals, nursing homes, physicians), drug stores, manufacturers and patients. Through its subsidiary companies, Bergen provides product distribution, logistics, pharmacy management programs, and Internet fulfillment strategies designed to reduce costs and improve patient outcomes across the entire healthcare spectrum. Bergen Brunswig press releases are available on the Company's website at www.bergenbrunswig.com.

Safe Harbor Statement

Except for historical information, all other information set forth in this press release, such as earnings forecasts and earnings rate projections, consists of "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These "forward-looking statements" are subject to risks, uncertainties and other factors which could cause actual results to differ materially from those projected or implied. Such statements may be identified by the use of forward-looking language such as "may," "will," "should," "expect," "anticipate," "estimate," "believe," "think," "continue" or the negatives or other variations thereof or other similar terminology. Such risks and uncertainties include the risks described in exhibit 99(a) to the Company's Annual Report on Form 10-K for the year ended September 30, 2000 and in other reports and exhibits filed with the Securities and Exchange Commission. These risks and uncertainties include, but are not limited to, the costs and difficulties related to the integration of acquired businesses, the loss or disruption of one or more key customer or supplier relationships, changes in the distribution outsourcing pattern for pharmaceutical products and/or services, the ability to obtain general financing or financing rates that would be compatible with the Company's business operations, and the costs and other effects of governmental regulation and legal and administrative proceedings. The Company assumes no obligation to update the information in the release.

Additional Information

In connection with their proposed merger, AmeriSource-Bergen, together with AmeriSource and Bergen Brunswig, filed a preliminary joint proxy statement/prospectus with the Securities and Exchange Commission. INVESTORS AND SECURITY HOLDERS ARE ADVISED TO READ THE DEFINITIVE JOINT PROXY STATEMENT/PROSPECTUS WHEN IT BECOMES AVAILABLE BECAUSE IT WILL CONTAIN IMPORTANT INFORMATION. Investors and security holders may obtain a free copy of the definitive joint proxy statement/prospectus (when available) and other documents filed by AmeriSource-Bergen (as well as by AmeriSource and Bergen Brunswig) at the Securities and Exchange Commission's web site at www.sec.gov. The definitive joint proxy statement/prospectus and such other documents may also be obtained for free from AmeriSource or from Bergen Brunswig by directing such request to AmeriSource Health Corporation, General Counsel, 1300 Morris Drive, Suite 100, Chesterbrook, Pennsylvania 19087-5594, Telephone: (610) 727-7000; or to Bergen Brunswig Corporation, Attention: Corporate Secretary, 4000 Metropolitan Drive, Orange, California 92868-3510, Telephone: (714) 385-4000.

Participants in Solicitation

AmeriSource and Bergen Brunswig and their respective directors, executive officers and other members of their management and employees may be deemed to be participants in the solicitation of proxies from their respective stockholders in connection with the proposed merger. Information concerning AmeriSource's participants in the solicitation is set forth in AmeriSource's Current Report on Form 8-K filed with the Securities and Exchange Commission on March 19, 2001, and information concerning Bergen Brunswig's participants in the solicitation is set forth in Bergen Brunswig's Current Report on Form 8-K filed with the Securities and Exchange Commission on March 19, 2001.

Bergen Brunswig Corporation

Index to Press Release Exhibits

For the Third Quarter and Nine Months Ended June 30, 2001

A. Summary of Consolidated Sales and Earnings for the Third Quarter and Nine Months Ended June 30, 2001 and 2000

B. Condensed Consolidated Balance Sheets as of June 30, 2001 and September 30, 2000

C. Summary of Consolidated Sales and Earnings from Continuing Operations for the Third Quarter Ended June 30, 2001 and 2000

D. Summary of Consolidated Sales and Earnings from Continuing Operations for the Nine Months Ended June 30, 2001 and 2000

E. Summary of Consolidated Sales, Operating Earnings and EBITDA by Business Segment for the Third Quarter Ended June 30, 2001 and 2000

F. Summary of Consolidated Sales, Operating Earnings and EBITDA by Business Segment for the Nine Months Ended June 30, 2001 and 2000

G. Key Operating Ratios for the Third Quarter and Nine Months
 Ended June 30, 2001 and 2000

Bergen Brunswig Corporation
 Summary of Consolidated Sales and Earnings
 (Unaudited)

(in thousands except per share amounts)	Third Quarter Ended		Nine Months Ended	
	June 30,		June 30,	
	2001	2000	2001	2000
Net sales and other revenues:				
Excluding bulk shipments to customers'				
warehouses	\$ 5,476,264	\$ 4,805,443	\$15,240,338	\$13,888,268
Bulk shipments to customers' warehouses	1,197,183	993,010	3,187,009	3,109,046

Total net sales and other revenues	6,673,447	5,798,453	18,427,347	16,997,314
Cost of sales	6,342,576	5,479,143	17,462,795	16,062,786

Gross profit	330,871	319,310	964,552	934,528
Distribution, selling, general and administrative expenses	232,234	245,607	700,264	717,079

Operating earnings from continuing operations	98,637	73,703	264,288	217,449
Net interest expense	32,540	31,974	101,674	80,627

Earnings from continuing operations before taxes on income and distributions on preferred securities of subsidiary trust	66,097	41,729	162,614	136,822
Taxes on income from continuing operations	27,387	18,490	67,319	61,935

Earnings from continuing operations before distributions on preferred securities of subsidiary trust	38,710	23,239	95,295	74,887
Distributions on preferred securities of subsidiary trust, net of income tax benefits	(3,526)	(3,526)	(10,578)	(10,578)

Earnings from continuing operations	35,184	19,713	84,717	64,309
Discontinued operations, net of income tax benefit:				
Loss from operations	- (8,199)	-	(20,850)	
Loss on dispositions	- (250,962)	-	(250,962)	

Net earnings (loss)	\$ 35,184	\$ (239,448)	\$ 84,717	\$ (207,503)

 Earnings (loss) per share:

Basic:				
Continuing operations	\$.26	\$.15	\$.63	\$.48
Discontinued operations:				
Loss from operations	- (.06)	- (.15)	- (.15)	- (.15)
Loss on dispositions	- (1.87)	- (1.87)	- (1.87)	- (1.87)
Net earnings (loss)	\$.26	\$ (1.78)	\$.63	\$ (1.54)

Diluted:				
Continuing operations	\$.26	\$.15	\$.62	\$.48
Discontinued operations:				
Loss from operations	- (.06)	- (.15)	- (.15)	- (.15)
Loss on dispositions	- (1.87)	- (1.87)	- (1.87)	- (1.87)
Net earnings (loss)	\$.26	\$ (1.78)	\$.62	\$ (1.54)

Weighted average number of shares outstanding:				
Basic	135,369	134,507	135,168	134,417
Diluted	137,327	134,519	136,824	134,491

A

Bergen Brunswick Corporation
Condensed Consolidated Balance Sheets
(Unaudited)

(in thousands)	June 30, 2001	September 30, 2000
Assets		
Cash and cash equivalents	\$ 60,804	\$ 94,032
Accounts and notes receivable(a)	1,280,629	1,232,300
Inventories	2,619,495	2,067,335
Other current assets	34,082	123,859
Total current assets	3,995,010	3,517,526
Goodwill -- net	663,268	658,640
Net property and other assets	352,095	395,258
Total assets	\$ 5,010,373	\$ 4,571,424
Liabilities and Shareowners' Equity		
Accounts payable	\$ 2,428,002	\$ 2,017,130
Current portion of long-term debt	54,335	22,364
Current portion of other long-term obligations	1,172	1,388
Other current liabilities	334,933	411,132
Total current liabilities	2,818,442	2,452,014
Long-term debt, net of current portion(a)	1,058,465	1,067,282
Other long-term obligations, net of current portion	23,957	28,879
Company-obligated mandatorily redeemable preferred securities of subsidiary trust holding solely debt securities of the Company	300,000	300,000
Shareowners' equity	809,509	723,249
Total liabilities and shareowners' equity	\$ 5,010,373	\$ 4,571,424

(a) Reduced by net proceeds of \$340,000 and \$168,000 at June 30, 2001 and September 30, 2000, respectively, from the sale of receivables under the Company's Receivables Securitization program.

B

Bergen Brunswig Corporation
Summary of Consolidated Sales and Earnings
From Continuing Operations
(Unaudited)

(in thousands except per share amounts)	Third Quarter Ended		Change	
	2001	June 30, 2000	Amount	Percent

Net sales and other revenues:				
Excluding bulk shipments to customers' warehouses	\$5,476,264	\$4,805,443	\$ 670,821	14 %
Bulk shipments to customers' warehouses	1,197,183	993,010	204,173	21 %

Total net sales and other revenues	6,673,447	5,798,453	874,994	15 %
Cost of sales	6,342,576	5,479,143	863,433	16 %

Gross profit -- LIFO	330,871	319,310	11,561	4 %
Distribution, selling, general and administrative expenses	232,234	245,607	(13,373)	(5)%

Operating earnings from continuing operations	98,637	73,703	24,934	34 %
Net interest expense	32,540	31,974	566	2 %

Earnings from continuing operations before taxes on income and distributions on preferred securities of subsidiary trust	66,097	41,729	24,368	58 %
Taxes on income from continuing operations	27,387	18,490	8,897	48 %

Earnings from continuing operations before distributions on preferred securities of subsidiary trust	38,710	23,239	15,471	67 %
Distributions on preferred securities of subsidiary trust, net of income tax benefit	(3,526)	(3,526)	-	-

Earnings from continuing operations	\$ 35,184	\$ 19,713	\$ 15,471	78 %

As a Percent of Revenue Excluding Bulk Shipments:				
Gross profit	6.04%	6.64%	(0.60)	
Distribution, selling, general and administrative expenses	4.24%	5.11%	(0.87)	

Operating earnings from continuing operations	1.80%	1.53%	0.27
Net interest expense	0.59%	0.67%	(0.08)
Earnings from continuing operations before taxes on income and distributions on preferred securities of subsidiary trust	1.21%	0.87%	0.34

Earnings per share from continuing operations:				
Basic	\$.26	\$.15	\$.11	73 %
Diluted	\$.26	\$.15	\$.11	73 %

Weighted average number of shares outstanding:		
Basic	135,369	134,507
Diluted	137,327	134,519

C

Bergen Brunswig Corporation
Summary of Consolidated Sales and Earnings
From Continuing Operations
(Unaudited)

(in thousands except per share amounts)	Nine Months Ended			
	2001	2000	Change Amount	Percent
Net sales and other revenues:				
Excluding bulk shipments to customers' warehouses	\$15,240,338	\$13,888,268	\$ 1,352,070	10 %
Bulk shipments to customers' warehouses	3,187,009	3,109,046	77,963	3 %
Total net sales and other revenues	18,427,347	16,997,314	1,430,033	8 %
Cost of sales	17,462,795	16,062,786	1,400,009	9 %
Gross profit -- LIFO	964,552	934,528	30,024	3 %
Distribution, selling, general and administrative expenses	700,264	717,079	(16,815)	(2)%
Operating earnings from continuing operations	264,288	217,449	46,839	22 %
Net interest expense	101,674	80,627	21,047	26 %
Earnings from continuing operations before taxes on income and distributions on preferred securities of subsidiary trust	162,614	136,822	25,792	19 %
Taxes on income from continuing operations	67,319	61,935	5,384	9 %
Earnings from continuing operations before distributions on preferred securities of subsidiary trust	95,295	74,887	20,408	27 %
Distributions on preferred securities of subsidiary trust,				

net of income tax benefit (10,578) (10,578) - -

Earnings from continuing operations \$ 84,717 \$ 64,309 \$ 20,408 32 %

As a Percent of Revenue Excluding

Bulk Shipments:

Gross profit	6.33%	6.73%	(0.40)
Distribution, selling, general and administrative expenses	4.60%	5.16%	(0.56)
Operating earnings from continuing operations	1.73%	1.57%	0.16
Net interest expense	0.67%	0.58%	0.09
Earnings from continuing operations before taxes on income and distributions on preferred securities of subsidiary trust	1.07%	0.99%	0.08

Earnings per share from continuing operations:

Basic	\$.63	\$.48	\$.15	31 %
Diluted	\$.62	\$.48	\$.14	29 %

Weighted average number of shares outstanding:

Basic	135,168	134,417
Diluted	136,824	134,491

D

Bergen Brunswig Corporation
Summary of Consolidated Sales, Operating Earnings and EBITDA
From Continuing Operations
By Business Segment
(Unaudited)

(dollars in thousands) Third Quarter Ended
June 30, Change
2001 2000 Amount Percent

Net Sales and Other Revenues:

Pharmaceutical Distribution	\$5,315,849	\$4,658,310	\$ 657,539	14 %
PharMerica	336,783	320,929	15,854	5 %
Other Businesses	228	262	(34)	(13)%
Corporate	235	(4)	239	N/M %
Intersegment Eliminations	(176,831)	(174,054)	(2,777)	(2)%

Revenue excluding bulk shipments 5,476,264 4,805,443 670,821 14 %

Bulk shipments of pharmaceuticals to customers' warehouses 1,197,183 993,010 204,173 21 %

Total \$6,673,447 \$5,798,453 \$ 874,994 15 %

Operating Earnings (Loss):

Pharmaceutical Distribution	\$ 102,488	\$ 91,477	\$ 11,011	12 %
PharMerica	16,002	(1,684)	17,686	N/M %
Other Businesses	(938)	(834)	(104)	(12)%
Corporate	(18,915)	(15,256)	(3,659)	(24)%

Total \$ 98,637 \$ 73,703 \$ 24,934 34 %

Operating Earnings (Loss) as a Percent of Revenue Excluding Bulk Shipments:

Pharmaceutical Distribution	1.93%	1.96%	(0.03)
PharMerica	4.75%	(0.52)%	5.27
Other Businesses	N/M	N/M	N/M

Total	1.80%	1.53%	0.27

Depreciation and Amortization:

Pharmaceutical Distribution	\$ 8,924	\$ 8,882	\$ 42	- %
PharMerica	7,476	10,909	(3,433)	(31)%
Other Businesses	80	76	4	5 %
Corporate	614	663	(49)	(7)%

Total	\$ 17,094	\$ 20,530	\$ (3,436)	(17)%

EBITDA:

Pharmaceutical Distribution	\$ 111,412	\$ 100,359	\$ 11,053	11 %
PharMerica	23,478	9,225	14,253	155 %
Other Businesses	(858)	(758)	(100)	(13)%
Corporate	(18,301)	(14,593)	(3,708)	(25)%

Total	\$ 115,731	\$ 94,233	\$ 21,498	23 %

N/M = Not Meaningful

E

Bergen Brunswig Corporation
Summary of Consolidated Sales, Operating Earnings and EBITDA
From Continuing Operations
By Business Segment
(Unaudited)

(dollars in thousands) Nine Months Ended
 June 30, Change
 2001 2000 Amount Percent

Net Sales and Other Revenues:

Pharmaceutical Distribution	\$14,792,711	\$13,450,480	\$ 1,342,231	10 %
PharMerica	1,011,873	950,429	61,444	6 %
Other Businesses	594	934	(340)	(36)%
Corporate	873	574	299	52 %
Intersegment Eliminations	(565,713)	(514,149)	(51,564)	(10)%

Revenue excluding bulk shipments 15,240,338 13,888,268 1,352,070 10 %

Bulk shipments of pharmaceuticals to customers' warehouses 3,187,009 3,109,046 77,963 3 %

Total \$18,427,347 \$16,997,314 \$ 1,430,033 8 %

Operating Earnings (Loss):

Pharmaceutical Distribution	\$ 275,790	\$ 253,801	\$ 21,989	9 %
PharMerica	47,267	14,550	32,717	225 %
Other Businesses	(2,694)	(2,457)	(237)	(10)%
Corporate	(56,075)	(48,445)	(7,630)	(16)%

Total	\$ 264,288	\$ 217,449	\$ 46,839	22 %

Operating Earnings (Loss) as a Percent of Revenue Excluding Bulk Shipments:

Pharmaceutical Distribution	1.86%	1.89%	(0.03)
PharMerica	4.67%	1.53%	3.14
Other Businesses	N/M	N/M	N/M

Total	1.73%	1.57%	0.16
-------	-------	-------	------

Depreciation and Amortization:

Pharmaceutical Distribution	\$ 26,635	\$ 26,656	\$ (21)	- %
PharMerica	22,506	33,054	(10,548)	(32)%
Other Businesses	243	227	16	7 %
Corporate	1,889	1,980	(91)	(5)%

Total	\$ 51,273	\$ 61,917	\$ (10,644)	(17)%
-------	-----------	-----------	-------------	-------

EBITDA:

Pharmaceutical Distribution	\$ 302,425	\$ 280,457	\$ 21,968	8 %
PharMerica	69,773	47,604	22,169	47 %
Other Businesses	(2,451)	(2,230)	(221)	(10)%
Corporate	(54,186)	(46,465)	(7,721)	(17)%

Total	\$ 315,561	\$ 279,366	\$ 36,195	13 %
-------	------------	------------	-----------	------

N/M = Not Meaningful

F

Bergen Brunswig Corporation
Key Operating Ratios
From Continuing Operations
(Unaudited)

(in thousands)	Third Quarter Ended		Nine Months Ended	
	June 30,	June 30,		
	2001	2000	2001	2000

Total Continuing Operations:

Revenues Excluding				
Bulk Shipments	\$ 5,476,264	\$ 4,805,443	\$15,240,338	\$13,888,268
Gross Profit --				
FIFO Basis	335,871	320,560	972,052	938,278
% of Revenues	6.13%	6.67%	6.38%	6.76%
Gross Profit --				
LIFO Basis	330,871	319,310	964,552	934,528
% of Revenues	6.04%	6.64%	6.33%	6.73%
DSG&A Expenses	232,234	245,607	700,264	717,079
% of Revenues	4.24%	5.11%	4.60%	5.16%
Operating Earnings --				
FIFO Basis	103,637	74,953	271,788	221,199
% of Revenues	1.89%	1.56%	1.78%	1.60%
Operating Earnings --				
LIFO Basis	98,637	73,703	264,288	217,449
% of Revenues	1.80%	1.53%	1.73%	1.57%
EBITDA -- FIFO Basis	120,731	95,483	323,061	283,116
% of Revenues	2.20%	1.99%	2.12%	2.04%
EBITDA -- LIFO Basis	115,731	94,233	315,561	279,366
% of Revenues	2.11%	1.96%	2.07%	2.01%

Pharmaceutical Distribution:

Revenues Excluding				
Bulk Shipments	\$ 5,315,849	\$ 4,658,310	\$14,792,711	\$13,450,480
Gross Profit --				
FIFO Basis	218,217	203,389	611,500	583,816
% of Revenues	4.10%	4.37%	4.13%	4.34%
Gross Profit --				
LIFO Basis	213,217	202,139	604,000	580,066
% of Revenues	4.01%	4.34%	4.08%	4.31%
DSG&A Expenses	110,729	110,662	328,210	326,265

% of Revenues	2.08%	2.38%	2.22%	2.42%
Operating Earnings --				
FIFO Basis	107,488	92,727	283,290	257,551
% of Revenues	2.02%	1.99%	1.91%	1.92%
Operating Earnings --				
LIFO Basis	102,488	91,477	275,790	253,801
% of Revenues	1.93%	1.96%	1.86%	1.89%
EBITDA -- FIFO Basis	116,412	101,609	309,925	284,207
% of Revenues	2.19%	2.18%	2.10%	2.11%
EBITDA -- LIFO Basis	111,412	100,359	302,425	280,457
% of Revenues	2.10%	2.15%	2.04%	2.09%

PharMerica:

Revenues Excluding				
Bulk Shipments	\$ 336,783	\$ 320,929	\$ 1,011,873	\$ 950,429
Gross Profit	117,191	116,913	359,085	352,954
% of Revenues	34.80%	36.43%	35.49%	37.14%
DSG&A Expenses	101,189	118,597	311,818	338,404
% of Revenues	30.05%	36.95%	30.82%	35.61%
Operating Earnings (Loss)	16,002	(1,684)	47,267	14,550
% of Revenues	4.75%	(0.52)%	4.67%	1.53%
EBITDA	23,478	9,225	69,773	47,604
% of Revenues	6.97%	2.87%	6.90%	5.01%

Change
vs. 2000
Quarter Nine Months

Total Continuing Operations:

Revenues Excluding		
Bulk Shipments	14%	10%
Gross Profit --		
FIFO Basis	5%	4%
% of Revenues	(0.54)	(0.38)
Gross Profit --		
LIFO Basis	4%	3%
% of Revenues	(0.60)	(0.40)
DSG&A Expenses	(5)%	(2)%
% of Revenues	(0.87)	(0.56)
Operating Earnings --		
FIFO Basis	38%	23%
% of Revenues	0.33	0.18
Operating Earnings --		
LIFO Basis	34%	22%
% of Revenues	0.27	0.16
EBITDA -- FIFO Basis	26%	14%
% of Revenues	0.21	0.08
EBITDA -- LIFO Basis	23%	13%
% of Revenues	0.15	0.06

Pharmaceutical Distribution:

Revenues Excluding		
Bulk Shipments	14%	10%
Gross Profit --		
FIFO Basis	7%	5%
% of Revenues	(0.27)	(0.21)
Gross Profit --		
LIFO Basis	5%	4%
% of Revenues	(0.33)	(0.23)
DSG&A Expenses	0%	1%
% of Revenues	(0.30)	(0.20)
Operating Earnings --		
FIFO Basis	16%	10%
% of Revenues	0.03	(0.01)

Operating Earnings --		
LIFO Basis	12%	9%
% of Revenues	(0.03)	(0.03)
EBITDA -- FIFO Basis	15%	9%
% of Revenues	0.01	(0.01)
EBITDA -- LIFO Basis	11%	8%
% of Revenues	(0.05)	(0.05)

PharMerica:

Revenues Excluding		
Bulk Shipments	5%	6%
Gross Profit	0%	2%
% of Revenues	(1.63)	(1.65)
DSG&A Expenses	(15)%	(8)%
% of Revenues	(6.90)	(4.79)
Operating Earnings (Loss)	N/M	225%
% of Revenues	5.27	3.14
EBITDA	155%	47%
% of Revenues	4.10	1.89